Economic Burden of COVID-19: A Systematic Review

Richards, F; Kodjamanova, Petya; Chen, Xue; Li, Nicole; Atanasov, Petar; Bennetts, Liga; Patterson, Brandon J.; Yektashenas, Behin; Mesa‐Frias, Marco; Tronczynski, Krzysztof; Büyükkaramikli, Nasuh; Khoury, Antoine C. El

doi:10.2147/ceor.s338225

Cited by 119 publications

(76 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early and accurate diagnosis of IFIs is essential to improving clinical outcomes and reducing the associated socio‐economic burden of these diseases 4 . Recently, IFIs have been identified as a complication in patients with Coronavirus disease 2019 (COVID‐19), 5–11 which, despite improvements in population immunity against the SARS‐CoV‐2 infection, remains an ongoing global issue associated with a significant clinical and economic burden 12–14 …”

Section: Introductionmentioning

confidence: 99%

“…4 Recently, IFIs have been identified as a complication in patients with Coronavirus disease 2019 (COVID-19), [5][6][7][8][9][10][11] which, despite improvements in population immunity against the SARS-CoV-2 infection, remains an ongoing global issue associated with a significant clinical and economic burden. [12][13][14] As with other viral respiratory diseases (e.g. influenza 15 ), IFIs are believed to develop as a consequence of severe lung damage and the immunological deficits associated with the COVID-19 SARS-CoV-2 infection or its treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secondary invasive fungal infection in hospitalised patients with COVID‐19 in the United States

Thompson

Miceli

Jiang

et al. 2023

Mycoses

View full text Add to dashboard Cite

Background: Invasive fungal infections (IFIs) have been identified as a complication in patients with Coronavirus disease 2019 (COVID-19). To date, there are few US studies examining the excess humanistic and economic burden of IFIs on hospitalised COVID-19 patients. Objectives: This study investigated the incidence, risk factors, clinical and economic burden of IFIs in patients hospitalised with COVID-19 in the United States. Patients/Methods: Data from adult patients hospitalised with COVID-19 during 01 April 2020-31 March 2021 were extracted retrospectively from the Premier Healthcare Database. IFI was defined either by diagnosis or microbiology findings plus systemic antifungal use. Disease burden attributable to IFI was estimated using time-dependent propensity score matching. Results: Overall, 515,391 COVID-19 patients were included (male 51.7%, median age: 66 years); IFI incidence was 0.35/1000 patient-days. Most patients did not have traditional host factors for IFI such as hematologic malignancies; COVID-19 treatments including mechanical ventilation and systemic corticosteroid use were identified as risk factors. Excess mortality attributable to IFI was estimated at 18.4%, and attributable excess hospital costs were $16,100. Conclusions: Invasive fungal infection incidence was lower than previously reported, possibly due to a conservative definition of IFI. Typical COVID-19 treatments were among the risk factors identified. Furthermore, diagnosis of IFIs in COVID-19 patients may be complicated because of the several non-specific shared symptoms, leading to underestimation of the true incidence rate. The healthcare burden of IFIs was significant among COVID-19 patients, including higher mortality and greater cost.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Secondary invasive fungal infection in hospitalised patients with COVID‐19 in the United States

Thompson

Miceli

Jiang

et al. 2023

Mycoses

View full text Add to dashboard Cite

show abstract

“…3 Based on the United States of America simulation, studies estimated the economic burden of COVID-19 as about 163.4 billion dollars only for medical costs. 4 High mortality rates, treatment costs, lockdowns, and many other factors have affected the economy and healthcare systems of many countries worldwide. 5 Coronaviruses are enveloped, positive-sense, singlestranded RNA and cause infection in many host species.…”

Section: Introductionmentioning

confidence: 99%

“…World health organization (WHO) estimated a mortality rate of 3.4% at the early stages of the COVID‐19 pandemic 3 . Based on the United States of America simulation, studies estimated the economic burden of COVID‐19 as about 163.4 billion dollars only for medical costs 4 . High mortality rates, treatment costs, lockdowns, and many other factors have affected the economy and healthcare systems of many countries worldwide 5 …”

Section: Introductionmentioning

confidence: 99%

COVID‐19 as a trigger of Guillain‐Barré syndrome: A review of the molecular mechanism

Malekpour

Khanmohammadi

Meybodi

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) caused a pandemic with serious complications. After coronavirus disease 2019 (COVID‐19), several post‐acute COVID‐19 syndromes (PACSs) and long‐COVID sequels were reported. PACSs involve many organs, including the nervous, gustatory, and immune systems. One of the PACSs after SARS‐CoV‐2 infection and vaccination is Guillain‐Barré syndrome (GBS). The incidence rate of GBS after SARS‐CoV‐2 infection or vaccination is low. However, the high prevalence of COVID‐19 and severe complications of GBS, for example, autonomic dysfunction and respiratory failure, highlight the importance of post‐COVID‐19 GBS. It is while patients with simultaneous COVID‐19 and GBS seem to have higher admission rates to the intensive care unit, and demyelination is more aggressive in post‐COVID‐19 GBS patients. SARS‐CoV‐2 can trigger GBS via several pathways like direct neurotropism and neurovirulence, microvascular dysfunction and oxidative stress, immune system disruption, molecular mimicry, and autoantibody production. Although there are few molecular studies on the molecular and cellular mechanisms of GBS occurrence after SARS‐CoV‐2 infection and vaccination, we aimed to discuss the possible pathomechanism of post‐COVID‐19 GBS by gathering the most recent molecular evidence.

show abstract

“…Since the initial identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in China on December 2019 ( Wu et al, 2020 ; Zhu et al, 2020 ), the ongoing pandemic of novel coronavirus disease 2019 (COVID-19) has placed a significant burden on health systems and economies ( Richards et al, 2022 ). Up to date (February 2023) there have been > 750,000,000 confirmed cases of SARS-CoV-2 infections reported to the World Health Organization with more than 6,800,000 estimated deaths worldwide.…”

Section: Introductionmentioning

confidence: 99%

Proof-of-concept for effective antiviral activity of an in silico designed decoy synthetic mRNA against SARS-CoV-2 in the Vero E6 cell-based infection model

et al. 2023

View full text Add to dashboard Cite

The positive-sense single-stranded (ss) RNA viruses of the Betacoronavirus (beta-CoV) genus can spillover from mammals to humans and are an ongoing threat to global health and commerce, as demonstrated by the current zoonotic pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current anti-viral strategies focus on vaccination or targeting key viral proteins with antibodies and drugs. However, the ongoing evolution of new variants that evade vaccination or may become drug-resistant is a major challenge. Thus, antiviral compounds that circumvent these obstacles are needed. Here we describe an innovative antiviral modality based on in silico designed fully synthetic mRNA that is replication incompetent in uninfected cells (termed herein PSCT: parasitic anti-SARS-CoV-2 transcript). The PSCT sequence was engineered to include key untranslated cis-acting regulatory RNA elements of the SARS-CoV-2 genome, so as to effectively compete for replication and packaging with the standard viral genome. Using the Vero E6 cell-culture based SARS-CoV-2 infection model, we determined that the intracellular delivery of liposome-encapsulated PSCT at 1 hour post infection significantly reduced intercellular SARS-CoV-2 replication and release into the extracellular milieu as compared to mock treatment. In summary, our findings are a proof-of-concept for the therapeutic feasibility of in silico designed mRNA compounds formulated to hinder the replication and packaging of ssRNA viruses sharing a comparable genomic-structure with beta-CoVs.

show abstract

Economic Burden of COVID-19: A Systematic Review

Cited by 119 publications

References 55 publications

Secondary invasive fungal infection in hospitalised patients with COVID‐19 in the United States

Secondary invasive fungal infection in hospitalised patients with COVID‐19 in the United States

COVID‐19 as a trigger of Guillain‐Barré syndrome: A review of the molecular mechanism

Proof-of-concept for effective antiviral activity of an in silico designed decoy synthetic mRNA against SARS-CoV-2 in the Vero E6 cell-based infection model

Contact Info

Product

Resources

About